Ken Ling
Impact in
- Biochemistry top 10%
-
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in ⓘ
-
- Sulfur Compounds in Biology 2
- Eicosanoids and Hypertension Pharmacology 1
- Co-authors
- Dawei Ye (3 shared papers)Ya‐Qun Zhou (1 shared paper)Fang Men (1 shared paper)Haowen Zhang (1 shared paper)Weici Wang (4 shared papers)Shanglong Yao (2 shared papers)Xiangdong Chen (2 shared papers)Chuanqi Cai (2 shared papers)
- Journals
- Journal of Medicinal Chemistry (1 paper)International Journal of Molecular Medicine (1 paper)Experimental Biology and Medicine (1 paper)Journal of Cardiothoracic and Vascular Anesthesia (1 paper)Frontiers in Public Health (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Ken Ling
7 papers receiving 500 citations
Peers
Comparison fields: 5 of 88
- Biochemistry 47
- Infectious Diseases 109
- Cell Biology 81
- Critical Care and Intensive Care Medicine 25
- Endocrine and Autonomic Systems 32
Countries citing papers authored by Ken Ling
This map shows the geographic impact of Ken Ling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Ling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Ling more than expected).
Fields of papers citing papers by Ken Ling
This network shows the impact of papers produced by Ken Ling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Ling. The network helps show where Ken Ling may publish in the future.
Co-authors
The 25 scholars most cited alongside Ken Ling, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 257 | |
| 2 | 2022 | 94 | |
| 3 | 2020 | 76 | |
| 4 | 2019 | 24 | |
| 5 | 2020 | 23 | |
| 6 | 2020 | 17 | |
| 7 | 2020 | 16 |
About Ken Ling
Ken Ling is a scholar working on Biochemistry, Internal Medicine, Critical Care and Intensive Care Medicine, Infectious Diseases and Neurology, having authored 7 papers that have together received 507 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (3 papers), Long-Term Effects of COVID-19 (2 papers), Sulfur Compounds in Biology (2 papers), Neonatal Health and Biochemistry (1 paper), Eicosanoids and Hypertension Pharmacology (1 paper), COVID-19 Impact on Reproduction (1 paper), Genomics, phytochemicals, and oxidative stress (1 paper) and Inflammasome and immune disorders (1 paper). The work is most often cited by research in Biochemistry (47 citations), Infectious Diseases (109 citations), Cell Biology (81 citations), Critical Care and Intensive Care Medicine (25 citations) and Endocrine and Autonomic Systems (32 citations). Ken Ling has collaborated with scholars based in China and United States. Frequent co-authors include Dawei Ye, Ya‐Qun Zhou, Fang Men, Haowen Zhang, Weici Wang, Shanglong Yao, Xiangdong Chen, Chuanqi Cai, Yi Guo and Yuxuan Li. Their work appears in journals such as Journal of Medicinal Chemistry, International Journal of Molecular Medicine, Experimental Biology and Medicine, Journal of Cardiothoracic and Vascular Anesthesia and Frontiers in Public Health.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.